GENE Genetic Technologies Ltd.

3.42-0.14 (-3.93%)
Close: February 24, 2020

Quote

Previous Close
-
Day Range
-
52 Week Range
$1.56-$6.32
Volume
37,763
Avg Volume
515,711
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$23.16M
Enterprise Value (EV)
$21.53M
PE Ratio
-
EV/EBITDA
-4.39
Price/Sales
1,265.36
Price/Book
18.63
PEG Ratio
-

Financials

Revenue
$18.20K
Gross Profit
-$179.38K
EBITDA
-$4.91M
EPS, ttm
-$0.98
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
-
Debt to Equity
-
Debt
-
Cash
$1.50M
Net Debt
-

Performance

Beta
0.62
200 Day Moving Avg
$2.55
50 Day Moving Avg
$3.27
52 Week Change
4.71%
YTD Change
67.22%
1 Month Change
-15.64%
3 Month Change
92.43%
6 Month Change
61.09%
1 Year Change
2.30%
2 Year Change
-48.85%
5 Year Change
-87.30%

Share Count

Shares Outstanding
6.8M
Float
-
Restricted Shares
6.8M
Restricted Shares, %
100.00%

Genetic Technologies Ltd. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Jerzy Muchnicki

Website: http://www.gtglabs.com

Description: Genetic Technologies Ltd. engages in the provision of molecular risk assessment for cancer. It operates through the USA and Australia geographical segments. Its product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.

Employees: -